Composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis and application thereof

A technology of pulmonary interstitial fibrosis and breviscapine, applied in drug combinations, medical preparations containing active ingredients, respiratory diseases, etc., can solve the problem of reversing the inflammatory process of pulmonary interstitial fibrosis Research or clinical research stage, lack of effectiveness and other issues, to achieve good anti-pulmonary fibrosis, simple preparation method and remarkable effect

Inactive Publication Date: 2010-06-30
XINXIANG MEDICAL UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the clinical treatment of pulmonary interstitial fibrosis mainly adopts hormones, immunosuppressants, cytotoxic drugs (such as thiazolin, cyclophosphamide) and anti-fibrotic agents (such as colchicine, D-cyanine, etc.). Mycamine) alone or in combination, but no matter which treatment method lacks effectiveness and has relatively large side effects
[0004] In addition, some new ideas and treatment methods have emerged for the treatment of pulmonary interstitial fibrosis, such as the use of cytokine inhibitors, anti-adhesion molecule antibodies, anti-C-C chemokines, antioxidants, antagonism of extracellular matrix deposition, Anti-protease, etc., but many of the above methods for treating pulmonary interstitial fibrosis are still in the stage of experimental research or clinical research
So far, there is no drug that can change or reverse the inflammatory process and fibrosis process of pulmonary interstitial fibrosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis and application thereof
  • Composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis and application thereof
  • Composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The preparation of embodiment 1 composition tablet (1000)

[0032] Formula: notoginseng saponin Rg1 (Kunming Pharmaceutical Factory, the following examples are all the same) 100g, scutellarin powder (Jiexiang Pharmaceutical Raw Materials Co., Ltd., the following examples are all the same) 200g, lactose 120g, MCC 50g, magnesium stearate 5g .

[0033] Preparation method: mix active ingredients, lactose and MCC evenly, moisten with water, then sieve through 18 mesh, dry, pass through 20 mesh sieve again, add magnesium stearate, mix evenly, and press into tablets.

Embodiment 2

[0034] The preparation of embodiment 2 composition tablet (1000)

[0035] Formula: breviscapine 300g, notoginseng saponin Rg1100g, sodium carboxymethyl starch 24g, magnesium stearate 5g.

[0036] Preparation method: mix active ingredients and MCC evenly, moisten with water, then sieve through 18 mesh, dry, pass through 20 mesh sieve again, add magnesium stearate, mix evenly, and tablet. The preparation of embodiment 3 composition capsules (1000)

[0037] Formula: breviscapine 200g, notoginseng saponin Rg1100g, lactose 80g, magnesium stearate 5g.

[0038] Preparation method: mix active ingredients and lactose evenly, moisten with water, pass through a 20-mesh sieve, dry, pass through a 22-mesh sieve again, add magnesium stearate, mix well, and pack into capsules. The preparation of embodiment 4 composition capsules (1000)

[0039] Formula: breviscapine 250g, notoginseng saponin Rg1100g, lactose 100g, magnesium stearate 15g.

[0040] Preparation method: mix active ingredient...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a composite of breviscapinum and panax notoginseng saponins Rg1 for treating pulmonary fibrosis, wherein the weight ratio of the breviscapinum to the panax notoginseng saponins Rg1 is 2-5:1-2. The invention also provides application of the composite in the preparation of a medicament for treating the pulmonary fibrosis. The composite of the breviscapinum and the panax notoginseng saponins Rg1 is formulated in a certain proportion and has the advantages of favorable pulmonary fibrosis resistance, remarkable effect and little side effects. Raw materials of the composite are easily obtained and can be prepared in various common dosage forms, such as tablets, capsules, injections and the like, through a conventional method with simple preparation method. The pharmacological action of the composite is obvious; in vitro, the composite can inhibit the activity of human embryonic lung fibroblasts and has favorable dosage dependence; and in vivo, the composite can lower the lung coefficient of a mouse with the pulmonary fibrosis and the content of hydroxyproline of lung tissues and also relieve the alveolitis of the mouse with the pulmonary fibrosis and reduce the degree of the pulmonary fibrosis.

Description

technical field [0001] The invention relates to a composition for treating pulmonary interstitial fibrosis, in particular to a composition composed of breviscapine and notoginsenoside Rg1, and the application of the composition in the preparation of medicines. Background technique [0002] Pulmonary interstitial fibrosis is a pulmonary interstitial lesion caused by different etiologies or unknown causes. Its pathological features are early alveolar structural destruction and diffuse alveolitis, followed by excessive deposition of extracellular matrix, and gradually develops into diffuse pulmonary fibrosis. Interstitial fibrosis, resulting in pulmonary dysfunction, most patients died of progressive respiratory failure. According to data, unexplained idiopathic pulmonary fibrosis (Idiopathicpulmonary Fibrosis, IPF) accounts for about 60-65% of pulmonary interstitial diseases, is the most common pulmonary interstitial disease, and its 5-year survival rate is lower than 50%, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/704A61P11/00
Inventor 詹合琴海广范郭兰青李鹏张小毅刘俊扇张崇
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap